Clinical Trial Update: 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

View source ↗

Summary

Clinical trial NCT05064306 evaluating 131I-omburtamab for central nervous system leptomeningeal neoplasms in children and young adults is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Leptomeningeal Neoplasms

Drugs mentioned

• 131I-omburtamab (omburtamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Central Nervous System/Leptomeningeal Neoplasms | Status: NO_LONGER_AVAILABLE